JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech’s 2024 sales surged 342% YoY, driven by a Takeda payment. read more
Genmab’s Tivdak wins Japan’s approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy. read more
Trump signs an order to create a Strategic Bitcoin Reserve. But the U.S. government is still not a buyer. Treasury Secretary says that might change. read more
Colgate-Palmolive and General Mills are poised for growth in the premium pet food market, with analysts projecting a 5% annual expansion through 2030. Innovation, increased advertising, and expanded production capacity are expected to drive sales, reinforcing their market position. Latest Ratings for CL Date Firm Action From To Feb 2022 Bernstein Upgrades Underperform Market Perform…
Canopy Growth (CGC) stock receives a Neutral rating from Zuanic & Associates, citing financial challenges and market uncertainties. Latest Ratings for CGC Date Firm Action From To Mar 2022 Barclays Maintains Equal-Weight Feb 2022 Cantor Fitzgerald Maintains Neutral Dec 2021 B of A Securities Downgrades Neutral Underperform View More Analyst Ratings for CGC View the…
Robinhood’s expansion into private banking targets young, tech-savvy investors with high-end financial services and is paying off, says Bernstein. read more